Coronary No-reflow Phenomenon
- PMID: 15913506
- DOI: 10.1007/s11936-005-0008-0
Coronary No-reflow Phenomenon
Abstract
No-reflow occurs in up to one third of patients with acute myocardial infarction during acute percutaneous intervention, and occasionally during elective interventions, particularly vein graft intervention. Multiple intracoronary medications will restore flow in most cases. We begin with 100 to 1000 mg of nitroprusside, verapamil, or adenosine at a similar dosage. We give it at 100-mg increments at high velocity. We inject it distally in the epicardial artery to avoid any systemic effect, and we do it through an intracoronary perfusion catheter. At times, we use prophylactic injections (prior to balloon inflation), particularly in vein graft intervention. Most of these strategies are not formally approved for treating no-reflow. However, reversing this condition with restoration of normal coronary flow is essential for an improved left ventricular function and a better cardiac outcome.
Similar articles
-
Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.J Am Coll Cardiol. 2001 Apr;37(5):1335-43. doi: 10.1016/s0735-1097(01)01138-x. J Am Coll Cardiol. 2001. PMID: 11300444
-
Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol.J Cardiovasc Med (Hagerstown). 2009 Jul;10(7):585-92. doi: 10.2459/JCM.0b013e32832b3571. J Cardiovasc Med (Hagerstown). 2009. PMID: 19384242 Clinical Trial.
-
Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction.Chest. 2005 Oct;128(4):2593-8. doi: 10.1378/chest.128.4.2593. Chest. 2005. PMID: 16236929 Clinical Trial.
-
Prophylactic intragraft injection of nicardipine prior to saphenous vein graft percutaneous intervention for the prevention of no-reflow: a review and comparison to protection devices.J Invasive Cardiol. 2011 May;23(5):202-6. J Invasive Cardiol. 2011. PMID: 21562350 Review.
-
Management of 'no-reflow' complicating reperfusion therapy.Acute Card Care. 2008;10(1):5-14. doi: 10.1080/17482940701744318. Acute Card Care. 2008. PMID: 18449813 Review.
Cited by
-
Factors Influencing the Risk of No-Reflow Development.Anatol J Cardiol. 2024 Mar 6;28(5):255-6. doi: 10.14744/AnatolJCardiol.2024.4224. Online ahead of print. Anatol J Cardiol. 2024. PMID: 38445623 Free PMC article. No abstract available.
-
A Machine Learning Model for the Prediction of No-Reflow Phenomenon in Acute Myocardial Infarction Using the CALLY Index.Diagnostics (Basel). 2024 Dec 14;14(24):2813. doi: 10.3390/diagnostics14242813. Diagnostics (Basel). 2024. PMID: 39767174 Free PMC article.
-
Acute alterations in glucose homeostasis impact coronary microvascular function in patients presenting with ST-segment elevation myocardial infarction.Neth Heart J. 2020 Mar;28(3):161-170. doi: 10.1007/s12471-020-01366-5. Neth Heart J. 2020. PMID: 31953778 Free PMC article.
-
Prevalence and prognostic implications of the no-reflux phenomenon in patients undergoing primary percutaneous coronary intervention at a university center in a middle-income country.Arch Cardiol Mex. 2024;94(3):331-340. doi: 10.24875/ACM.23000120. Arch Cardiol Mex. 2024. PMID: 39028873 Free PMC article. English.
-
Percutaneous Coronary Intervention Induced-No-reflow in Saphenous Vein Grafts.Arq Bras Cardiol. 2024 Sep 23;121(8):e20240317. doi: 10.36660/abc.20240317. eCollection 2024. Arq Bras Cardiol. 2024. PMID: 39319879 Free PMC article. English, Portuguese. No abstract available.
References
LinkOut - more resources
Full Text Sources